GlassScriptPhysician profile
Timothy T Mccay
NPI 1245221761
$678.30
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $273 · 2021: $59.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $96.43 | 2019-2021 | |
| Lilly USA, LLC | $94.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.50 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $51.36 | 2020 | |
| Curium US LLC | $46.44 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.49 | 2019 | |
| Genzyme Corporation | $35.75 | 2019 | |
| Seagen INC. | $32.85 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $30.06 | 2020 | |
| Puma Biotechnology, INC. | $26.88 | 2019 | |
| Astellas Pharma US INC | $21.61 | 2020 | |
| Amgen INC. | $16.69 | 2021 | |
| Daiichi Sankyo INC. | $16.29 | 2020 | |
| Genentech USA, INC. | $14.54 | 2019 | |
| Pfizer INC. | $14.17 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $12.51 | 2019 | |
| Eisai INC. | $11.91 | 2020 | |
| Novo Nordisk INC | $11.84 | 2019 | |
| Epizyme, INC. | $11.80 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mccay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.